December 8, 2025
Agentic AI could transform treatment…
Artificial intelligence (AI) is helping to transform the….
Introducing PropheSee™
AI-powered predictive model and intervention platform from CCS built for healthcare organizations focused on improving CGM device adherence and outcomes for people living with diabetes.
Data
The Source of Our Data is Unique
CCS’s AI-powered predictive model leverages 800+ member, clinical, supply, and consumer-centric attributes.
Health, Consumer, SDoH
Customer Engagement
Medical Supply Point-of-Sale
“Our payor and provider partners must expect that AI insights will drive the supply and service of our chronic care patients today and well into the future. It’s not enough to serve the patient a product or service and fulfill a transaction. A value-based care future and answer to delivering a better integrated healthcare experience requires this kind of digital investment and fluency."
Richard Mackey
Chief Technology Officer | CCS
Impact
Derive Insights, Influence Behaviors
Our data offers tremendous insights that, when properly aligned, allow CCS to offer the member a hyper-personalized experience to best manage their care. It anticipates the member’s needs and allows CCS to support them to maintain product therapy adherence.
Your Members, Our Insights
Introducing CCS’s Predictive Model
“Greater adherence to CGM devices improves glycemic control, preventing complications and hospital admissions as a result of those complications. Better health outcomes means substantial reduction in total cost of care for insurers while device non-adherence leads to significant waste of financial resources and the forfeiting of long-term health benefits and cost savings that effective diabetes management provides.”
Coni Dennis
SVP, Chief Clinical Officer | CCS
Predictive Analytics
Promoting Adherence and Persistence
We help elevate health plans through comprehensive, member-centric diabetes management by focusing on four key areas.
Proprietary Data
185+ proprietary data element inputs to provide real-time insights, avoiding the typical delay seen from using only claims data.
Predictive Accuracy
We know when a patient is likely to become nonadherent with 86% predictive accuracy for future adherence within a 30-day forward window.
Hyper-personalized Interventions
Distinct personas drive interventions, from custom messaging to relevant support, to help prevent lapses in care.
Improved Adherence
With the deployment of PropheSee, CCS has observed increases in adherence rates among targeted, high-risk patient cohorts by as much as 50% compared to control groups.
“The innovative, advanced analytics predictive model that Accenture collaborated with CCS to develop will help identify patients at risk of non-adherence to diabetic treatment up to 90 days in advance. Taking real-time, personalized action, the tool intends to drive better adherence and improved outcomes. Trusted studies suggest that better engagement with patients leads to better health outcomes and overall quality of life.”
Chinmoy Barua
Managing Director, Data & AI Practice Lead | Accenture
CCS in the News
June 19, 2025
AI-powered nudges for chronic disease…
AI needs to know when, where, and how….
May 13, 2025
New Data Show CCS’s Predictive…
CCS, a leading provider of clinical solutions and….